Patent ID: 9192665
Filing Date: 2015-11-24
Classification: A61K,A61P,C07K

Abstract:
1. A method for treating a tumorous mass of lymph node tissue and/or extranodal lymphoma in a patient suffering from relapsed and/or refractory diffuse large B cell lymphoma (DLBCL), the method comprising the step of administering to the patient (i) a composition comprising an effective amount of a CD19×CD3 bispecific antibody in a step-wise application, whereby a first dose between 1 and 15 μg/m 2 /d of the CD19×CD3 bispecific antibody is administered daily for a first period of time from 3 to 10 days, a second dose between 1 and 15 μg/m 2 /d of the CD19×CD3 bispecific antibody is administered daily for a second period of time from 3 to 10 days, and a third dose between 15 and 60 μg/m 2 /d of the CD19×CD3 bispecific antibody is administered daily for a third period of time from 8 to 78 days; and (ii) a composition comprising an effective amount of a glucocorticoid to ameliorate adverse neurological effects of the antibody in the patient, whereby the glucocorticoid is administered prior to and after the CD19×CD3 bispecific antibody is administered.